Pfizer Inc (PFE) Files Form 4 Insider Selling : Douglas M Lankler Sells 29,700 Shares

Pfizer Inc (PFE): Douglas M Lankler , Executive Vice President of Pfizer Inc sold 29,700 shares on May 4, 2016. The Insider selling transaction was reported by the company on May 5, 2016 to the Securities and Exchange Commission. The shares were sold at $33.69 per share for a total value of $1,000,557.88 , the company said in a SEC Form 4 Filing.

Other Insider transactions have been reported by the company according to SEC Form 4, on May 5, 2016, Frank A Damelio (Executive Vice President) sold 87,079 shares at $33.65 per share price.On Aug 3, 2015, Loretta V Cangialosi (Sr. Vice President, Controller) sold 24,704 shares at $35.65 per share price.Also, On Jun 12, 2015, Laurie J Olson (Executive Vice President) sold 26,000 shares at $34.38 per share price.On Jun 2, 2015, Charles H Hill (Executive Vice President) sold 42,870 shares at $34.92 per share price.

Shares of Pfizer (PFE) ended Wednesday, May 4, 2016 session in red amid volatile trading. The shares closed down -0.3 points or -0.89% at $33.4 with 3,60,73,395 shares getting traded. Post opening the session at $33.67, the shares hit an intraday low of $33.33 and an intraday high of $33.9 and the price vacillated in this range throughout the day. The company has a market cap of $206,550 M and the number of outstanding shares has been calculated to be 6,18,41,40,000 shares. The 52-week high of Pfizer is $36.46 and the 52-week low is $28.25.

Pfizer Money Flow Index Chart

Company has been under the radar of several Street Analysts.Pfizer is Reiterated by UBS to Buy and the brokerage firm has raised the Price Target to $ 38 from a previous price target of $36 .The Rating was issued on May 4, 2016.Pfizer is Resumed by Goldman to Neutral and the brokerage firm has set the Price Target at $35. The Rating was issued on Apr 18, 2016.Pfizer is Resumed by JP Morgan to Overweight and the brokerage firm has set the Price Target at $38. The Rating was issued on Apr 7, 2016.Pfizer is Resumed by Morgan Stanley to Equal-Weight and the brokerage firm has set the Price Target at $35. The Rating was issued on Apr 7, 2016.

Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering developing and manufacturing of healthcare products. Its products include Lyrica the Prevnar family of products Enbrel Celebrex Lipitor Viagra Zyvox Sutent EpiPen Toviaz Tygacil Rapamune Xalkori Inlyta Norvasc BeneFIX Genotropin and Enbrel among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP) Global Vaccines Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing registering and commercializing medications in therapeutic areas such as inflammation cardiovascular/metabolic neuroscience and pain rare diseases and women’s/men’s health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira Inc.

Leave a Reply

Pfizer - Is it time to Sell?

Top Brokerage Firms are advising their investors on Pfizer. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.